𝐅𝐫𝐨𝐦 𝐌𝐨𝐥𝐞𝐜𝐮𝐥𝐞𝐬 𝐭𝐨 𝐌𝐞𝐚𝐧𝐢𝐧𝐠: 𝐋𝐞𝐯𝐞𝐫𝐚𝐠𝐢𝐧𝐠 𝐈𝐧𝐬𝐢𝐠𝐡𝐭 𝐭𝐨 𝐓𝐫𝐚𝐧𝐬𝐟𝐨𝐫𝐦 𝐃𝐚𝐭𝐚 𝐢𝐧𝐭𝐨 𝐃𝐞𝐜𝐢𝐬𝐢𝐨𝐧𝐬

-An exclusive interview with Mr VINOD DUA, Strategic Director, Pfarmex Healthtech, Paulomi Roy

Q1. What challenges do companies face in handling insights today?
The biggest challenge is fragmentation—scientific data sits across reports, decks, and informal channels. Insights often arrive too late to guide the decisions. The data is treated as a task rather than an asset. Despite heavy investments, less than 20% of insights shape strategy. The challenge is not the information scarcity but interpretation lags.

Q2. Why is Medical Affairs (MA) becoming so critical now?
MA is the scientific conscience of an organization but has often been limited to compliance in India. When empowered, it bridges clinical outcomes, post-marketing evidence, and field learnings. In branded generics market, the medical narrative is a key differentiator.

Q3. What makes Pfarmex’s approach unique?
PfarmexTM brings structured intelligence to an area traditionally driven by individual interpretation. It blends evidence aggregation, real-time insights, and strategic context, difficult to scale with manual model. Insights are the new currency of differentiation. The platform focuses on connecting insights across Medical, Marketing & Business Development.

Q4. With AI advancing, can insights processes be automated?
Yes, responsibly. AI can aggregate insights and analyse real-world evidence, but interpretation must remain human-led. Technology should enhance judgement, not replace it.

Q5. What advice would you give to pharma leaders?
Innovation is not only about new molecules but also about unlocking value from existing knowledge. Manufacturing built strength, but insight will drive differentiation. Valuing medical and field insights alongside sales performance can elevate both scientific credibility and business outcomes.